ORI Capital is spearheading a significant growth phase in Chinese biotechnology by raising $350 million for its third investment fund. China has recently secured six of the top ten global…
Merck is establishing a $1 billion biologics center of excellence in Wilmington, Delaware, aiming to boost innovation and the local economy. The facility will focus on the production of Keytruda,…
Biotechnology, integrating biology with technology, is a key area of innovation where China seeks global dominance. China's state-supported strategy includes acquiring, amplifying, and dominating global markets, challenging competitors through low…
Biotechnology's infrastructure is crucial for innovation in health and agriculture but lacks adequate national security protection. The National Security Commission on Emerging Biotechnology urges classifying biotechnology alongside critical sectors like…
Profound transformation is occurring in energy trading, encompassing oil, biofuels, carbon, ammonia, and hydrogen. Quantum Commodity Intelligence offers a platform for accessing insights into global markets, aiding informed decisions. Timely…
The digital interaction between humans and technology is a complex symphony, with every user action monitored by security protocols. Human curiosity during intense online activities can sometimes mimic bot behavior,…
Digital interactions face a delicate balance between vigilance and intrusive surveillance. Rapid data browsing may trigger account suspensions, misinterpreted as suspicious activity. Automated detection systems aim to protect data integrity…
Peter J. Weiler appointed as new Chief Financial Officer of Edesa Biotech, effective May 1, 2025. Weiler brings extensive experience from his previous roles at Exzell Pharma, Biosyent Inc., and…
Edesa Biotech appoints Peter J. Weiler as CFO starting May 1, 2025, succeeding Stephen Lemieux. Weiler brings extensive experience from leadership roles at Exzell Pharma and Biosyent Inc., blending scientific…
Edesa Biotech has appointed Peter J. Weiler as its new Chief Financial Officer, effective May 1, 2025. Weiler brings extensive experience from leadership roles at Exzell Pharma, Biosyent Inc., and…